Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic.
Boni, Maciej F
Bull, Matthew J
Colquhoun, Rachel M
McCrone, John T
Nicholls, Samuel M
Webster, Hermione J
COVID-19 Genomics UK (COG-UK) Consortium,
Loman, Nicholas J
Connor, Thomas R
Robertson, David L
Pybus, Oliver G
MetadataShow full item record
Jackson, B., Boni, M. F., Bull, M. J., Colleran, A., Colquhoun, R. M., Darby, A. C., Haldenby, S., et al. (2021). Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic.. Cell, 184 (20), 5179-5188.e8. https://doi.org/10.1016/j.cell.2021.08.014
We present evidence for multiple independent origins of recombinant SARS-CoV-2 viruses sampled from late 2020 and early 2021 in the United Kingdom. Their genomes carry single-nucleotide polymorphisms and deletions that are characteristic of the B.1.1.7 variant of concern but lack the full complement of lineage-defining mutations. Instead, the remainder of their genomes share contiguous genetic variation with non-B.1.1.7 viruses circulating in the same geographic area at the same time as the recombinants. In four instances, there was evidence for onward transmission of a recombinant-origin virus, including one transmission cluster of 45 sequenced cases over the course of 2 months. The inferred genomic locations of recombination breakpoints suggest that every community-transmitted recombinant virus inherited its spike region from a B.1.1.7 parental virus, consistent with a transmission advantage for B.1.1.7's set of mutations.
COVID-19 Genomics UK (COG-UK) Consortium, Humans, Computational Biology, Phylogeny, Recombination, Genetic, Base Sequence, Gene Frequency, Genotype, Mutation, Polymorphism, Single Nucleotide, Genome, Viral, Pandemics, United Kingdom, Whole Genome Sequencing, COVID-19, SARS-CoV-2
The COG-UK Consortium is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) (MC_PC_19027), and Genome Research Limited, operating as the Wellcome Sanger Institute. O.G.P. was supported by the Oxford Martin School. J.T.M., R.M.C., N.J.L., and A.R. acknowledge the support of the Wellcome Trust (Collaborators Award 206298/Z/17/Z – ARTIC network). D.L.R. acknowledges the support of the MRC (MC_UU_12014/12) and the Wellcome Trust (220977/Z/20/Z). E.S. and A.R. are supported by the European Research Council (grant agreement no. 725422 – ReservoirDOCS). T.R.C. and N.J.L. acknowledge the support of the MRC, which provided the funding for the MRC CLIMB infrastructure used to analyze, store, and share the UK sequencing dataset (MR/L015080/1 and MR/T030062/1). The samples sequenced in Wales were sequenced partly using funding provided by the Welsh Government.
Medical Research Council (MC_PC_19027)
External DOI: https://doi.org/10.1016/j.cell.2021.08.014
This record's URL: https://www.repository.cam.ac.uk/handle/1810/329067
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/